<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) remains the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the world </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately in 50 percent of patients, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> is a major cause of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, early diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is crucial for a successful outcome </plain></SENT>
<SENT sid="3" pm="."><plain>For the detection of circulating <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, this study applied a sensitive method that employed specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers for early detection </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A total of 80 blood samples from 40 CRC patients and 40 age-matched healthy controls were collected for the study </plain></SENT>
<SENT sid="5" pm="."><plain>The circulating <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> endothelial marker 8 (TEM-8) and carcinoembryogenic antigen (CEA) were evaluated using an absolute quantitative real-time PCR assay in a Stratagene Mx-3000P real-time PCR system </plain></SENT>
<SENT sid="6" pm="."><plain>GAPDH was used as the endogenous control </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: TEM-8 and CEA were primarily detected more in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients rather than in the controls: 22/40 vs 9/40, p=0.009 and 30/40 vs 11/40, p=0.00054, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, the <z:chebi fb="2" ids="33699">mRNA</z:chebi> level of these markers was significantly higher in comparison to the <z:mpath ids='MPATH_458'>normal</z:mpath> controls (p=0.018 and 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>The overall sensitivity of this panel was 65% with a specificity of 75% </plain></SENT>
<SENT sid="10" pm="."><plain>Statistical analysis for demographic variants did not reach significant values </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: TEM-8 and CEA markers were detected more frequently and in significantly higher levels in the blood samples of patients compared with samples from age-matched healthy controls </plain></SENT>
<SENT sid="12" pm="."><plain>The copy number of CEA and TEM-8 mRNA, as detected by a real-time quantitative PCR, appears to be a promising marker for evaluating the risk of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> spread </plain></SENT>
</text></document>